ru-66647 has been researched along with cefditoren* in 2 studies
1 review(s) available for ru-66647 and cefditoren
Article | Year |
---|---|
New antimicrobial molecules and new antibiotic strategies.
Drug options for treatment of infections are increasingly limited. The pharmaceutical industry has found it difficult to discover new antimicrobial agents, and only two novel classes of antibiotics, the oxazolidinones and the cyclic lipopeptides, have entered the market since the late 1960s. Few new agents have reached the market in the last decade with potential interest for community-acquired pneumonia (CAP) treatment, including linezolid (the first oxazolidinone in clinical use), new fluoroquinolones, cefditoren, ertapenem, and telithromycin. Agents currently in clinical development include other novel quinolones and ketolides, broad-spectrum cephalosporin derivatives, faropenem, several glycopeptides, and iclaprim. Other molecules are considered to be promising candidates for the future. In addition to the foregoing agents, alternative treatment approaches have also been introduced into clinical practice, which include the administration of the appropriate antimicrobials in a timely manner and the consideration of the pharmacokinetic-pharmacodynamic properties of the agent(s). Topics: Acetamides; Anti-Infective Agents; beta-Lactams; Cephalosporins; Community-Acquired Infections; Drug Design; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Ertapenem; Fluoroquinolones; Humans; Ketolides; Linezolid; Lipopeptides; Oxazolidinones; Pneumonia, Bacterial; Practice Guidelines as Topic | 2009 |
1 other study(ies) available for ru-66647 and cefditoren
Article | Year |
---|---|
In vitro activities of oral cephem and telithromycin against clinical isolates of major respiratory pathogens in Japan.
The in vitro antibacterial activities of oral cephem antibiotics and ketolide telithromycin against major respiratory pathogens possessing beta-lactam-resistant mutations (within the pbp gene) and/or macrolide-resistant genes (erm and mef) were examined in clinical isolates collected at 66 institutes in all over the Japan between 2002 and 2003. Telithromycin showed the strongest antibacterial activity against methicillinsusceptible Staphylococcus aureus strains with and without macrolide-resistant genes, such as ermA or ermC gene. All the cephem antibiotics showed potent antibacterial activity against Streptococcus pyogenes, with minimum inhibitory concentrations (MICs) of 0.015 mg/L or lower. Cefdinir had a much higher MIC90 against genotypic penicillin-resistant Streptococcus pneumoniae (gPRSP) than cefditoren and cefcapene (8 mg/L cefdinir vs. 1 mg/L cefditoren and cefcapene). The majority of gPRSP harbored either ermB or mefA, and the antibacterial activity of telithromycin against these strains was decreased however some susceptibility was still sustained. Cefditoren exerted the strongest antibacterial activity against beta-lactamase-negative ampicillin-resistant Haemophilus influenzae, with an MIC90 of 0.5 mg/L. These results underline the importance of checking the susceptibility and selecting an appropriate antibiotic against target pathogens. Topics: Administration, Oral; Cephalosporins; Haemophilus influenzae; Humans; Ketolides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes | 2007 |